Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., and Eli Lilly and Co., of Indianapolis, said the FDA issued a complete response letter for their new drug application (NDA) for sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin. The agency referenced previously observed deficiencies at a Boehringer Ingelheim facility where empagliflozin will be manufactured.